This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MediPoint: Total Ankle Replacement - US Analysis And Market Forecasts

NEW YORK, April 11, 2013 /PRNewswire/ announces that a new market research report is available in its catalogue:

MediPoint: Total Ankle Replacement - US Analysis and Market Forecasts

MediPoint: Total Ankle Replacement - US Analysis and Market Forecasts

SummaryAnkle arthritis is a severe and debilitating problem with notable increasing prevalence in both the developed and developing world. In a society constantly seeking out a modern lifestyle, sports-related injuries, trauma, aging, and obesity are contributing to an increased incidence of ankle arthritis. Total ankle replacement (TAR) enables implantation of prosthesis within the diseased native ankle joint to help patients maintain their ankles' range of motion. Promising results of newer generation prostheses revived interest in TAR and fueled further innovations in the prosthetic design. After decades of trial and error, TAR is now becoming a promising option for late-stage ankle arthritis patients as an alternative to ankle fusion, which has historically been presumed to be the gold-standard procedure. This report focuses on the TAR markets in the US. This report identifies unmet needs in the market, surgeon attitudes towards current TAR prostheses, and the future of TAR in the face of rapid technological advancement.

Early experience with TAR in the US was met with unacceptable failure and complication rates in the 1980s, such that the procedure was largely abandoned. In the past decade, newer generations of TAR prostheses with a more anatomical replication of the ankle joint demonstrated some encouraging early and medium-term clinical results. Meanwhile, long-term results following successful early ankle fusion have brought to light somewhat disappointing long-term satisfaction rates. TAR is becoming an increasingly popular alternative to ankle fusion lately, as professional and commercial interest intensifies and long-term effectiveness becomes available.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs